MedTech SuperConnector supports early stage medical technology businesses through education and resources, self-described as an accelerator programme for medical technology innovators.

MedTech SuperConnector

Imperial Enterprise Lab is a support service dedicated to students, staff, and alumni for developing entrepreneurial mindsets, skills, and networks. It provides assistance in testing new ideas and launching products, services, and ventures to address real-world challenges.

Imperial Enterprise Lab

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Shwen Gwee

Johann Rudolf

Joerg Reinhardt

Alexander Clavel

Novartis AG

Buckinghamshire New University offers higher education courses and programs in various disciplines, focusing on student support and employability.

Buckinghamshire New University

MedTech SuperConnector is dedicated to empowering medical technology innovators to develop and scale impactful medical technologies. It supports Early Career Researchers with high-potential medical technologies to achieve their innovation aspirations and create impactful healthcare solutions.

MedTech SuperConnector | 2,156 followers on LinkedIn. A collaboration of institutions with a shared vision to support Early Career Researchers to develop medtech innovations. | Funded by Research England, MedTech SuperConnector is an initiative from a consortium of eight dynamic London universities, with interest in nurturing talent, ideas, and entrepreneurship, led by Imperial College London. MTSC will focus uniquely on a new route for Post-Docs and graduate students, to translate MedTech discoveries from academic labs into startup companies, proposing more solutions to today’s health challenges.

8 HEI Consortium Partners:

The Francis Crick Institute | Institute of Cancer Research | Imperial College London | Queen Mary University of London | Royal College of Art | Bucks New University | Royal Veterinary College University of London | Royal College of Music London

Managing Director, GGS Associates

Gerard Gregg-Smith

London IVD - NIHR Imperial College London | Co Founder Vita Healthcare Solutions | Exec ED Lecturer | Mentor | Healthcare Innovation Consultant

Omar Butt

Early-stage Innovation Specialist at Imperial College London | MBA

Hiten Thakrar, MBA

👋 Say hello to our new cohort of innovators in the MSK Innovation Accelerator powered by Orthopaedic Research UK ! 👋 Our cohort came together for 3 action-packed days to kickstart their innovation journey, expertly led by our facilitator, Omar Butt . Highlights of the Bootcamp included: 🌟 Workshops on Investment Readiness, Innovating in the NHS, Leadership and Product Adoption from Nav Chana Johnny Craike Shahryar Barati Paul Stevens 🌟 Insightful introductions to industry leaders, Cedric Steenbeke and Neil Christie, from NVIDIA and ScanAI Technologies Inc. Connect with our fabulous cohort here: Manoj Patel | Harsha Siani | Antony Raymond | Arjan Atwal | Sophie Richter | Ali Abdi | Adele Hill | Kabelan J Karunaseelan | Dylan Ashton | Renyang Gu We can't wait to see what the next 6 months has in store for our innovators! Imperial College London | Imperial Enterprise Lab | Hiten Thakrar, MBA | Candice Middleton, PhD | Bonnie Zhang | Anne Roques | Arash Angadji | Martin Thomas | Toni A.

⚠️ Join Our Info Session at 12 PM ⚠️ It’s not too late! Join us today at 12 PM for a deep dive into the MSK Innovation Accelerator. Learn how you can transform your idea into a reality with the right support and resources. 👉 https://lnkd.in/eV958jkc We can’t wait to see you there! Orthopaedic Research UK | Imperial College London | Imperial Enterprise Lab | Omar Butt | Arash Angadji | Toni A. | Hiten Thakrar, MBA | Candice Middleton, PhD | Bonnie Zhang

🚀 Join Us Tomorrow for the MSK Innovation Accelerator Info Session! 🚀 Don’t miss our online session tomorrow, September 26th, at 12 PM. Learn about the programme, ask your questions, and get ready to take your MSK innovation to the next level! 👉 https://lnkd.in/eV958jkc Orthopaedic Research UK | Imperial College London | Imperial Enterprise Lab | Omar Butt | Arash Angadji | Toni A. | Hiten Thakrar, MBA | Candice Middleton, PhD | Bonnie Zhang

🗓️ Join Our MSK Innovation Accelerator Info Session on September 26th! 🗓️ Curious about the MSK Innovation Accelerator? Join us for an online information session on September 26th at 12 PM to learn all about the programme, its benefits, and how it can help bring your innovation to life. Find out if this accelerator is the right fit for you! 🔗 https://lnkd.in/eV958jkc Orthopaedic Research UK | Imperial College London | Imperial Enterprise Lab | MedTechONE | Omar Butt | Arash Angadji | Toni A. | Hiten Thakrar, MBA | Candice Middleton, PhD | Bonnie Zhang #MSK #MedTech #Innovation #Healthcare #InfoSession

Metric
Company Name	MedTech SuperConnector	Imperial Enterprise Lab	Novartis AG	Buckinghamshire New University
Symbol			NOVN
MSH ID	COM:MEDTECHSUPERCONNECTOR	COM:IMPERIALENTERPRISELAB	COM:NOVARTIS	UK:AC:BUCKS
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Commercial & Professional Services	Commercial & Professional Services		Commercial & Professional Services
Industry	Medical Technology	Business Support Services		Education
Country	GB	GB	CH	GB
Stage
Employee Count			101.70K
Website	medtechsuperconnector.com	imperialenterpriselab.com	novartis.com	bucks.ac.uk
LinkedIn	medtech-superconnector		novartis	uk.linkedin.com/school/buckinghamshirenewuniversity/
Founders

Metric
Market Cap		220.95B
Enterprise Value
Monthly Web Traffic	3.40K		130.86K
Web Traffic Growth	0.66		-0.16
Valuation
Raised Capital

Metric
Revenue			46.66B
Revenue (LTM)
Revenue (NTM)
Gross Profit			34.19B
EBITDA			18.47B
Operating Income			9.77B
Net Income			14.85B
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.75
Operating Profit Margin			0.25
EBITDA Margin			0.40
Net Profit Margin			0.33
Return on Equity			0.39
Return on Assets			0.17
Return on Capital Employed			0.17

COM:MEDTECHSUPERCONNECTOR

MedTech SuperConnector

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			14.33
P/B Ratio			4.56
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			4.83
EV Multiple			11.29

Metric
Days Sales Outstanding			67.09
Days Payables Outstanding			124.77
Days Inventory Outstanding			169.11
Operating Cycle			232.40
Cash Conversion Cycle			110.44
Asset Turnover			0.53

Metric
Operating Cash Flow			14.46B
Free Cash Flow			11.71B
Cash Flow to Debt			0.55
Operating Cash Flow/Sales			0.31
Free Cash Flow Yield			0.05

Metric
Cash & Equivalents			13.39B
Accounts Receivable			-1.50B
Inventory			5.91B
Goodwill			23.34B
Debt to Capitalization			0.41
Debt to Assets			0.26
Current Ratio			1.16
Quick Ratio			0.88

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.02
R&D to Revenue			0.23
SG&A to Revenue